Equity | India | Cosmetics/Personal Care 01 November 2010

## Bank of America Merrill Lynch

Anuj Bansal >> Research Analyst DSP Merrill Lynch (India) anuj.bansal@baml.com +91 22 6632 8690

#### Stock Data

Price	Rs424.10
Price Objective	Rs470.00
Date Established	1-Nov-2010
Investment Opinion	C-1-7
Volatility Risk	HIGH
52-Week Range	Rs225.00-Rs484.80
Mrkt Val / Shares Out (mn)	US\$3,089 / 323.6
Average Daily Volume	347,652
BofAML Ticker / Exchange	XGOCF / BSE
Bloomberg / Reuters	GCPL IN / GOCP.BO
ROE (2011E)	36.3%
Net Dbt to Eqty (Mar-2010A)	-28.1%
Est. 5-Yr EPS / DPS Growth	20.0% / 20.0%
Free Float	30.7%

#### Key Changes

(Rs)	Previous	Current
Price Obj.	400.00	470.00
2011E Rev (m)	37,010.7	36,898.9
2012E Rev (m)	45,645.2	45,779.8
2013E Rev (m)	52,849.6	53,002.4
2011E EPS	14.82	15.51
2012E EPS	18.51	19.69
2013E EPS	22.18	23.49

# Visibility improves on strong Sep Q results; Buy

#### Acquisition benefit starts to flow in; PO raised to Rs470

Sep Q profit of Rs1.3bn was up 40% yoy beating our est by 27% on lower interest costs, higher other op income & lower tax. Operating profit in line with our est as higher sales growth was offset by lower margins. We have raised our est by 5-6% over FY11-12E to factor in lower interest cost & higher other op income. Maintain Buy and raise PO to Rs470 to factor in earnings raise and higher multiple 24x (vs 22x) on expected re-rating on better visibility on earnings post the strong Sep Q.

#### Domestic business weakness continues; Expect revival

Soaps declined 10% on low primary sales as de-stocking of high inventory levels continued. Hair Colors revived with 20% growth (12% vol growth). Though we have cut domestic est by 6-7% to factor in the current weakness, we are not concerned for long term health as 1) market share trends are positive 2) we expect revival in 2H as normal monsoons lead to fall in inflation & support rural demand and 3) favorable base as inventory de-stocking is now behind us.

#### Godrej Household products continues to outperform

GHPL sales grew 38% yoy led by new product launches and rising demand from disease threat in India. Our confidence on 25% sales growth and EBITDA margin of 21-22% is reaffirmed post this strong performance. GHPL is also generating additional royalty income from Megasari for its share of R&D efforts. This has led to Other income surprise in this qtr which we have adjusted for going forward.

#### New international acquisitions are a mixed bag

Existing international business of Keyline and Rapidol had weak growth on tough market conditions and unfavorable currency move. Also, Tura in Africa and Issue Group in LAtAm performed weaker than expected as GCPL is investing significantly behind these companies. However, Megasari, largest international biz of GCPL has done well beating the expected 20% growth with 20% margin est.

#### Estimates (Mar)

\* For full definitions of iQmethod SM measures, see page 9.

2009A	2010A	2011E	2012E	2013E
1,726	3,396	5,020	6,372	7,603
6.72	11.02	15.51	19.69	23.49
-4.7%	64.0%	40.8%	26.9%	19.3%
4.00	4.08	4.65	5.91	7.05
6.52	8.25	13.64	17.89	23.15
2009A	2010A	2011E	2012E	2013E
63.14x	38.49x	27.34x	21.54x	18.05x
0.943%	0.963%	1.10%	1.39%	1.66%
75.59x	38.26x	22.63x	17.56x	14.79x
1.22%	1.85%	3.22%	4.22%	5.46%
	1,726 6.72 -4.7% 4.00 6.52 2009A 63.14x 0.943% 75.59x	1,726 3,396 6.72 11.02 -4.7% 64.0% 4.00 4.08 6.52 8.25 2009A 2010A 63.14x 38.49x 0.943% 0.963% 75.59x 38.26x	1,726 3,396 5,020 6.72 11.02 15.51 -4.7% 64.0% 40.8% 4.00 4.08 4.65 6.52 8.25 13.64  2009A 2010A 2011E 63.14x 38.49x 27.34x 0.943% 0.963% 1.10% 75.59x 38.26x 22.63x	1,726 3,396 5,020 6,372 6.72 11.02 15.51 19.69 -4.7% 64.0% 40.8% 26.9% 4.00 4.08 4.65 5.91 6.52 8.25 13.64 17.89  2009A 2010A 2011E 2012E 63.14x 38.49x 27.34x 21.54x 0.943% 0.963% 1.10% 1.39% 75.59x 38.26x 22.63x 17.56x

>> Employed by a non-US affiliate of MLPF&S and is not registered/qualified as a research analyst under the FINRA rules.

Refer to "Other Important Disclosures" for information on certain BofA Merrill Lynch entities that take responsibility for this report in particular jurisdictions.

BofA Merrill Lynch does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## *iQprofile*<sup>™</sup> Godrej Consumer Products Ltd.

Key Income Statement Data (Mar)	2009A	2010A	2011E	2012E	2013E
(Rs Millions)					
Sales	13,966	20,437	36,899	45,780	53,002
Gross Profit	6,271	10,934	18,966	23,348	27,031
Sell General & Admin Expense	(4,197)	(6,836)	(12,038)	(14,419)	(16,431)
Operating Profit	1,882	3,862	6,416	8,398	10,051
Net Interest & Other Income	211	337	19	(123)	(47
Associates	NA	NA	NA	NA	N/
Pretax Income	2,092	4,199	6,435	8,275	10,004
Tax (expense) / Benefit	(366)	(803)	(1,416)	(1,903)	(2,401
Net Income (Adjusted)	1,726	3,396	5,020	6,372	7,603
Average Fully Diluted Shares Outstanding	257	308	324	324	324
Key Cash Flow Statement Data					
Net Income	1,726	3,396	5,020	6,372	7,603
Depreciation & Amortization	192	236	512	531	549
Change in Working Capital	(242)	(327)	(816)	(813)	(361
Deferred Taxation Charge	NA	NA	NA	NA	N/
Other Adjustments, Net	0	0	0	0	(
Cash Flow from Operations	1,676	3,305	4,715	6,090	7,79
Capital Expenditure	0	(763)	(300)	(300)	(300
(Acquisition) / Disposal of Investments	NA	NA	NA	NA	N/
Other Cash Inflow / (Outflow)	183	(595)	0	0	(222
Cash Flow from Investing	183	(1,358)	(300)	(300)	(300
Shares Issue / (Repurchase)	3,648	2,175	5,313	0	(0.440
Cost of Dividends Paid	(1,203)	(1,490)	(1,762)	(2,237)	(2,669
Cash Flow from Financing	3,350	(1,722)	23,851	(5,839)	(7,573
Free Cash Flow Net Debt	1,676	2,543	4,415	5,790	7,49
Change in Net Debt	(1,008) (4,305)	(2,683) (2,633)	19,457 (7,966)	15,923 (3,554)	11,119 (4,822)
Key Balance Sheet Data	(4,303)	(2,033)	(7,700)	(3,334)	(4,022
	2 207	2 / 2 /	2 / 00	2.470	2.24
Property, Plant & Equipment	2,297	2,626	2,690	2,478	2,247
Other Non-Current Assets	2,207 602	3,789	33,677	33,677	33,67
Trade Receivables	3,783	1,153	2,029 1,212	2,747	3,180 1,04
Cash & Equivalents Other Current Assets	2,852	3,052 4,834	8,671	1,144 10,987	
Total Assets	2,652 11,742	4,634 15,452	48,279	51,033	12,72° 52,868
Long-Term Debt	2,776	369	20,669	17,067	12,163
Other Non-Current Liabilities	42	66	20,007	66	12,10
Short-Term Debt	NA	NA	NA	NA	N.A
Other Current Liabilities	3,299	5,528	9,427	11,647	13,452
Total Liabilities	6,117	5,963	30,161	28,779	25,68
Total Equity	5,715	9,547	18,118	22,253	27,188
Total Equity & Liabilities	11,832	15,510	48,279	51,032	52,869
iQmethod <sup>™</sup> - Bus Performance*					
Return On Capital Employed	28.6%	38.0%	22.2%	17.6%	20.4%
Return On Equity	46.6%	44.5%	36.3%	31.6%	30.8%
Operating Margin	13.5%	18.9%	17.4%	18.3%	19.0%
EBITDA Margin	14.8%	20.1%	18.8%	19.5%	20.0%
<i>iQmethod</i> <sup>™</sup> - Quality of Earnings*		23.170	. 3.070	. 7.0 70	20.07
Cash Realization Ratio	1.0x	1.0x	0.9x	1.0x	1.0
Asset Replacement Ratio	0x	3.2x	0.9x 0.6x	0.6x	0.5
Tax Rate (Reported)	17.5%	19.1%	22.0%	23.0%	24.0%
Net Debt-to-Equity Ratio	-17.6%	-28.1%	107.4%	71.6%	40.9%
Interest Cover	NA	34.8x	107.470 12.4x	12.7x	17.2
Key Metrics *For full definitions of iOmethod 5M measures see page 9	IVA	J4.0X	12.48	12./٨	17.

<sup>\*</sup> For full definitions of *iQmethod* <sup>SM</sup> measures, see page 9.


#### **Company Description**

Godrej Consumer is among the leading FMCG companies in India - second largest player in soaps and largest in hair color. It has market leading brands particularly in the economy and mid segments. It also has presence in other toiletries and detergents. Over the last few years it has made a number of overseas acquisitions mainly in developing countries. International business accounts for 25% of its total business.

#### **Investment Thesis**

Godrej is a Buy as we expect strong earnings growth to sustain. Recent spate of acquisitions is positive. It helps to drive earnings growth through synergies and also further diversifies business. Fear of slowdown in domestic business is cushioned post GSL stake hike. We expect Godrej to continue to rerate as its earnings growth should be one of the strongest within sector. Upside risk is higher than expected benefit from synergies post integration. Downside risk is slower than expected growth.

Chart 1: Sales mix (FY11E)



Source: Banc of America Securities - Merrill Lynch Estimates

#### Stock Data

Price to Book Value 7.6x



## Sep Q results reaffirm confidence

GCPL Sep Q net profit of Rs1.3bn was up 40% yoy, beating our estimates by 27%. Key reasons for surprise were 1) lower interest cost 2) higher other operating income and 3) lower tax. .

#### Domestic business should turnaround going forward

Sales decline of 3% in domestic business was below expectations as inventory de-stocking in soaps continued for longer than expected. But on the positive side, hair colors revived growth with 20% value growth during the quarter. Going forward we expect sales growth to pick up as inventory de-stocking is behind us and we are entering into a period of favorable base.

#### Godrej Household Products continues to shine

With 38% yoy sales growth, GHPL beat expectations. This strong growth was led by new product launches and surge in demand on rising concerns of malaria and dengue spread. Margins were however muted in this quarter as A&P spends went up to support new launches. Post this strong Sep Q, our confidence on a 25% sales growth with 21-22% margin is reaffirmed.

#### Market share gains across all categories is a positive

We are encouraged by the favorable market share trend for Godrej Consumers. It gained 20bp in hair colors and 350bp in household insecticides. Soaps also managed to retain healthy market share of 10.4%. This highlights the sustenance of consumer demand for GCPL despite lower primary sales.

#### Margin pressure to continue on input costs and A&P spends

EBITDA margin declined 170bp vs our estimates of 60bp decline. This was on higher than expected hit from rising input costs especially palm oil. Also, A&P spends in both domestic and international operations remained high. This hit the margins by 140bp. Though GCPL does have cushion of exceptionally high staff costs of last year, we believe high A&P spends and rising input costs will continue to create pressure on margins.

#### Growth of existing international operations weak

Keyline, the UK business of GCPL declined 8% during the quarter on high base of last year, weak market conditions and Re appreciation. Also, the existing South African business had a weak 8% growth on slowdown in economic conditions of the country.

#### New acquisitions - mixed performance emerges

While the largest international business – Megasari continued to do well with what we believe to be a 20%+ growth and 21% EBITDA margin, the other two recent acquisitions were weaker than expected. Both Tura in Nigeria and Issue in LatAm will require higher A&P support to ramp up operations. So while the sales growth in both these businesses is likely to remain strong, the profitability in the near term will be an issue.



Table 1: Results highlights - Consolidated

Year Ending March 31	Q2 10	Q2 11	% chg	1H 10	1H 11	%chg
Net Sales	5,756	9,528	66%	10,144	15,959	57%
Total Material costs	2,714	4,619	70%	4,736	7,787	64%
As %	47.2%	48.5%	1.3%	46.7%	48.8%	2.1%
Staff costs	576.2	803.6	39%	950	1,242	31%
Advertising & Sales Promotion	509.4	979.5	92%	943	1,630	73%
As %	8.9%	10.3%	1.4%	9.3%	10.2%	
Other expenditure	836.6	1435.8	72%	1,533	2,418	58%
EBITDA	1,119	1,690	51%	1,984	2,881	45%
EBITDA margin	19.4%	17.7%	-1.7%	19.6%	18.1%	-1.5%
Depreciation	67.6	154.5		120	239	
EBIT	1052	1535	46%	1,864	2,643	42%
Interest	26.1	88.9		64	194	
Profit bef OI	1026	1447	41%	1,800	2,449	36%
Other Income	138.8	194		240	278	
Pretax profit	1164	1641	41%	2,040	2,727	34%
Total Tax	234	338		414	577	
Tax rate	20.1%	20.6%		20.3%	21.2%	-0.8%
Net profit	930	1302	40%	1,627	2,150	32%
Shares O/S	308	325		308	325	
EPS	3.0	4.0	33%	5	7	25%

Source: Company, Banc of America Securities - Merrill Lynch Estimates

#### Chart 2: EPS and EPS growth trends



Source: Company, Banc of America Securities - Merrill Lynch Estimates


## Earnings growth remains strong; Buy

We have raised our EPS estimates for GCPL by 5-6% for FY11-12E to factor in current surprise in earnings from better performance from Godrej Household Products, lower interest cost and higher other operational income. This is despite a lower earnings estimate in domestic business for which have cut the earnings estimates by 6-7% and also some cut in earnings in international business other than Megasari. With we now have an EPS CAGR of 34% over FY10-12E.

#### Domestic growth revival should be strong in 2H


We believe the problem with slowdown in Soaps is temporary and hair color has already showed revival. Market share trends for both the categories indicate consumer demand remains strong. Clearly, trade de-stocking is a near term phenomenon and growth should revive when normal trade inventory levels are restored. Also, with monsoons running normal, growth should revive in 2H when food inflation comes off and there is support from rural demand.

Chart 3: Soaps - Value and volume growth trends



Source: Company, Banc of America Securities - Merrill Lynch Estimates

Chart 4: Hair color - Value and volume growth trends



Source: Company, Banc of America Securities - Merrill Lynch Estimates

### Chart 5: Interest cost and net gearing trends



Source: Company, Banc of America Securities - Merrill Lynch Estimates

#### Godrej Household Products continues to do well

Godrej Household Products (aka Godrej Sara Lee) continues to do well with 38% sales growth during the quarter. This gives us confidence that GHPL should achieve our 25% growth estimate for FY11-12E. Synergies from combined distribution are yet to be realized and that should help to improve sales (especially in North India) and also rationalize distribution costs. Also, GHPL is earning royalty from Megasari for the shared R&D effort. This is has led to the surprise in other operating income in this quarter and we have adjusted our estimates going forward for this income.

#### Ex-Megasari growth in international business is the key

At this point in time we are not concerned about slowdown in international businesses of GCPL. We have already factored in a much weaker Keyline and also had moderate expectations from South African businesses. Sub par performance by Tura and Issue are not encouraging. However, given that their sales growth is strong but profits are hit due to higher investment behind brands, we remain hopeful of strong earnings growth once the investment phase is over.

Megasari continues to grow strongly and is crucial for overall performance as it commands ~40% of the total international business for GCPL. We remain hopeful of a 20% growth with a 21-22% margin for Megasari.

#### Synergy led growth in recent acquisitions could surprise

We remain confident of synergies surprising on the upside from recent acquisitions. Most of these could however have an impact only from FY12E onwards post the stabilization of the acquired businesses. We therefore due to lack of visibility and non availability of longer term trends maintain our conservative growth estimates of ~15-20% for these acquisitions. This remains the key upside risk to our earnings estimates.

#### Low interest costs are now built in

Interest costs hold potential for significant positive surprise. US\$350mn loan is currently held at US 6m LIBOR + 150-175bp. This at current LIBOR levels implies a rate of interest of only 2% pa. We had conservatively assumed our interest costs at 5-6% pa to factor in possible hedging costs. However, given the surprise in quarterly results continues to be significant on this count, we have now built in an interest rate of 3-4% over FY11-13E.

### Maintain Buy; PO raised to Rs470

Given the strong earnings CAGR of 34% over FY11-12E we maintain Buy rating on Godrej Consumers. We believe there is strong case of earnings upgrades coming through in 2HFY11 led by 1) revival in domestic business 2) lower interest costs 3) higher than expected growth from international acquisitions. We maintain raise our PO to Rs470 at 24xFY12E EPS of Rs19.7.



## Summarized financial estimates

Table 2: Summarized earnings estimates - Consolidated

(Rs mn)	FY09A	FY10A	FY11E	FY12E	FY13E
Net Sales	13,966	20,437	36,899	45,780	53,002
% chg	27%	46%	81%	24%	16%
Standalone	10,491	12,679	13,288	15,075	17,106
International	3,130	3,782	11,933	15,477	17,980
Sara Lee		4,068	11,393	14,942	17,632
EBITDA - Total	2,074	4,098	6,928	8,929	10,600
EBIDTA - standalone	1,603	2,660	2,579	2,949	3,409
EBIDTA - international	471	595	1,956	2,767	3,312
EBITDA - Sara Lee		773	2,393	3,213	3,879
EBITDA Margin	14.8%	20.1%	18.8%	19.5%	20.0%
Depreciation	192	236	512	531	549
EBIT	1,882	3,862	6,416	8,398	10,051
% chg	-5%	105%	66%	31%	20%
Net interest cost / (income)	(211)	(337)	(19)	123	47
PBT	2,092	4,199	6,435	8,275	10,004
Total Tax	366	803	1,416	1,903	2,401
Tax Rate	17.5%	19.1%	22.0%	23.0%	24.0%
Net Profit	1,726	3,396	5,020	6,372	7,603
% chg	8%	97%	48%	27%	19%
EPS	6.7	11.0	15.5	19.7	23.5
% chg	-5%	64%	41%	27%	19%

Source: Company, BofA Merrill Lynch Global Research Estimates

Table 3: Summarized balance sheet estimates - Consolidated

. abio or oaiiiiiaiizoa baiaiioo	orroot oothina				
(Rs mn)	FY09A	FY10A	FY11E	FY12E	FY13E
Share Capital	257	308	324	324	324
Reserves	5,458	9,239	17,794	21,929	26,864
Loans	2,776	369	20,669	17,067	12,163
Deferred Tax Liability	42	66	66	66	66
Current Liabilities	2,919	5,326	9,225	11,445	13,251
Provisions	380	202	202	202	202
Total Liabilities	11,832	15,510	48,279	51,032	52,869
Net Fixed Assets	2,297	2,626	2,690	2,478	2,247
Goodwill	2,132	3,119	33,007	33,007	33,007
Investments	75	670	670	670	670
Inventories	1,675	2,644	4,981	6,409	7,420
Debtors	602	1,153	2,029	2,747	3,180
Loans and Advances	1,178	2,189	3,690	4,578	5,300
Total Cash	3,783	3,052	1,212	1,144	1,044
Total Current Assets (ex cash)	3,544	6,044	10,701	13,734	15,901
Total Assets	11832	15510	48279	51033	52868

Source: Company, BofA Merrill Lynch Global Research Estimates



Table 4: Summarized cashflow estimates - Consolidated

(Rs mn)	FY09A	FY10A	FY11E	FY12E	FY13E
Profit after tax	1,726	3,396	5,020	6,372	7,603
Add depr	192	236	512	531	549
Cash bef W Cap changes	1,918	3,632	5,531	6,903	8,152
Working cap change	(242)	(327)	(816)	(813)	(361)
Cash from operations	1,676	3,305	4,715	6,090	7,791
(Incr) / Decr in Fixed Assets	258	(763)	(300)	(300)	(300)
(Incr) / Decr in Investments	(75)	(595)	-	-	-
(Incr)/Decr in Goodwill	(1,176)	(986)	(29,888)	-	-
Free cash flow	683	962	(25,473)	5,790	7,491
Incr / (decr) in Equity	3,648	2,175	5,313	-	-
Incr / (decr) in Debt	905	(2,407)	20,300	(3,602)	(4,904)
Dividend & Div tax payout	(1,203)	(1,490)	(1,762)	(2,237)	(2,669)
Total Cash from financing	3,350	(1,722)	23,851	(5,839)	(7,573)
Total cash flow	4,033	(760)	(1,622)	(48)	(82)

Source: Company, BofA Merrill Lynch Global Research Estimates

Table 5: Key Ratios

	FY09A	FY10A	FY11E	FY12E	FY13E
Net debt/Equity	-18%	-28%	107%	72%	41%
RoCE	18%	25%	16%	13%	15%
RoE	47%	45%	36%	32%	31%
EV/EBITDA	49.1	29.4	21.5	16.3	13.3

Source: Company, BofA Merrill Lynch Global Research Estimates

### Price objective basis & risk

#### Godrej Consumer Products Ltd. (XGOCF)

Our preferred valuation methodology is a target P/E multiple on one year forward EPS. Our target multiple for Godrej is 24x, which on FY12E EPS of Rs19.7 gives us our price objective of Rs470. Our target multiple is at 10pc premium to the FMCG universe and last 5-year trading multiple for Godrej. We believe this premium is justified given expected stronger earnings CAGR of 34pc over FY11-12E. Upside risks are better than expected top-line growth, higher synergies from international acquisitions. Downside risks are lower than expected margin expansion on rising palm oil prices and low visibility on performance of international business.

#### Link to Definitions

#### Consumer & Retail

Click here for definitions of commonly used terms.

#### **Analyst Certification**

I, Anuj Bansal, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

#### **Special Disclosures**

In accordance with the SEBI (Foreign Institutional Investors) Regulations and with guidelines issued by the Securities and Exchange Board of India (SEBI), foreign investors (individuals as well as institutional) that wish to transact the common stock of Indian companies must have applied to, and have been approved by SEBI and the Reserve Bank of India (RBI). Each investor who transacts common stock of Indian companies will be required to certify approval as a foreign institutional investor or as a sub-account of a foreign institutional investor by SEBI and RBI. Certain other entities are also entitled to transact common stock of Indian companies under the Indian laws relating to investment by foreigners. BofA Merrill Lynch reserves the right to refuse copy of research on common stock of Indian companies to a person not resident in India. American Depositary Receipts (ADR) representing such common stock are not subject to these Indian law restrictions and may be transacted by investors in accordance with the applicable laws of the relevant jurisdiction. Global Depository Receipts (GDR) and the Global Depository Shares of Indian companies, Indian limited liability corporations, have not been registered under the U.S. Securities Act of 1933, as amended, and may only be transacted by persons in the United States who are Qualified Institutional Buyers (QIBs) within the meaning of Rule 144A under the Securities Act. Accordingly, no copy of any research report on Indian companies' GDRs will be made available to persons who are not QIBs.

India - Consumer Coverage Cluster

Investment rating	Company	BofAML ticker	Bloomberg symbol	Analyst
BUY				
	Asian Paints	XAPNF	APNT IN	Anuj Bansal
	Colgate India	CPIYF	CLGT IN	Anuj Bansal
	Dabur India	DBUIF	DABUR IN	Anuj Bansal
	Godrej Consumer Products Ltd.	XGOCF	GCPL IN	Anuj Bansal



#### India - Consumer Coverage Cluster

Investment rating	Company	BofAML ticker	Bloomberg symbol	Analyst
_	ITC Limited	ITCTF	ITC IN	Anuj Bansal
	K S Oils Limited	XKSOF	KSO IN	Prasad Deshmukh
	Mcleod Russel India Ltd.	XCVFF	MCLR IN	Prasad Deshmukh
	Pantaloon	PFIAF	PF IN	Anuj Bansal
	Radico Khaitan	RKHAF	RDCK IN	Anuj Bansal
	Titan Industries Ltd	TTNIF	TTAN IN	Anuj Bansal
	United Spirits	UDSRF	UNSP IN	Anuj Bansal
UNDERPERFORM				
	Hindustan Unilever	HINLF	HUVR IN	Anuj Bansal
	Nestle India	XNTEF	NEST IN	Anuj Bansal
	Shoppers' Stop	XPQUF	SHOP IN	Anuj Bansal

#### iOmethod<sup>™</sup> Measures Definitions

ignieinoa ivicasures Den	HILIOHS	
<b>Business Performance</b>	Numerator	Denominator
Return On Capital Employed	NOPAT = (EBIT + Interest Income) * (1 - Tax Rate) + Goodwill	Total Assets - Current Liabilities + ST Debt + Accumulated Goodwill
	Amortization	Amortization
Return On Equity	Net Income	Shareholders' Equity
Operating Margin	Operating Profit	Sales
Earnings Growth	Expected 5-Year CAGR From Latest Actual	N/A
Free Cash Flow	Cash Flow From Operations – Total Capex	N/A
Quality of Farnings		

Quality of Earnings

Cash Realization Ratio Cash Flow From Operations Net Income Asset Replacement Ratio Capex Depreciation Tax Rate Tax Charge Pre-Tax Income Net Debt-To-Equity Ratio Net Debt = Total Debt, Less Cash & Equivalents **Total Equity** Interest Cover Interest Expense

**Valuation Toolkit** 

Price / Earnings Ratio Current Share Price Diluted Earnings Per Share (Basis As Specified) Price / Book Value **Current Share Price** Shareholders' Equity / Current Basic Shares

Dividend Yield Annualised Declared Cash Dividend **Current Share Price** 

Free Cash Flow Yield Cash Flow From Operations – Total Capex Market Cap. = Current Share Price \* Current Basic Shares

Enterprise Value / Sales EV = Current Share Price \* Current Shares + Minority Equity + Net Debt + Sales

Other LT Liabilities

EV / EBITDA Enterprise Value Basic EBIT + Depreciation + Amortization


iQmethod swis the set of BofA Merrill Lynch standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.

iQdatabase® is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Merrill Lynch.

iQprofile M, iQmethod M are service marks of Merrill Lynch & Co., Inc.iQdatabase sis a registered service mark of Merrill Lynch & Co., Inc.

### **Important Disclosures**

#### **XGOCF Price Chart**



B: Buy, N: Neutral, S: Sell, U: Underperform, PO: Price objective, NA: No longer valid, NR: No Rating

"Prior to May 31, 2008, the investment opinion system included Buy, Neutral and Sell. As of May 31, 2008, the investment opinion system includes Buy, Neutral and Underperform. Dark Grey shading indicates that a security is under review with the opinion withdrawn. The current investment opinion key is contained at the end of the report. Chart is current as of August 31, 2010 or such later date as indicated. BofA Merrill Lynch price charts do not reflect analysts' coverage of the stock at prior firms."

Investment Rating Distribution: Consumer Products Group (as of 01 Oct 2010)

Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	35	53.85%	Buy	17	53.13%
Neutral	14	21.54%	Neutral	7	58.33%
Sell	16	24.62%	Sell	7	43.75%
<b>Investment Rating Distribution: G</b>	Global Group (as of 01 (	Oct 2010)			
Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	1948	54.31%	Buy	821	46.73%
Neutral	891	24.84%	Neutral	397	49.07%
Sell	748	20.85%	Sell	259	37.16%

<sup>\*</sup> Companies in respect of which MLPF&S or one of its affiliates has received compensation for investment banking services within the past 12 months. For purposes of this distribution, a stock rated Underperform is included as a Sell.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. *VOLATILITY RISK RATINGS*, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. *INVESTMENT RATINGS* reflect the analyst's assessment of a stock's: (i) absolute total return potential and (ii) attractiveness for investment relative to other stocks within its *Coverage Cluster* (defined below). There are three investment ratings: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster\*

Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

<sup>\*</sup> Ratings dispersions may vary from time to time where BofAML Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofAML Comment referencing the stock.

Price charts for the securities referenced in this research report are available at http://pricecharts.ml.com, or call 1-888-ML-CHART to have them mailed. In the US, retail sales and/or distribution of this report may be made only in states where these securities are exempt from registration or have been qualified for sale: Godrej Consumer.

The country in which this company is organized has certain laws or regulations that limit or restrict ownership of the company's shares by nationals of other countries: Godrej Consumer.

The analyst(s) responsible for covering the securities in this report receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking revenues.



### Other Important Disclosures

Officers of MLPF&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

BofA Merrill Lynch Global Research policies relating to conflicts of interest are described at http://www.ml.com/media/43347.pdf.

"BofA Merrill Lynch" includes Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") and its affiliates. Investors should contact their BofA Merrill Lynch representative or Merrill Lynch Global Wealth Management financial advisor if they have questions concerning this report.

Information relating to Non-US affiliates of BofA Merrill Lynch and Distribution of Affiliate Research Reports:

MLPF&S and BASL distribute, or may in the future distribute, research reports of the following non-US affiliates in the US (short name: legal name): Merrill Lynch (France): Merrill Lynch Capital Markets (France) SAS; Merrill Lynch (Irankfurt): Merrill Lynch International Bank Ltd, Frankfurt Branch; Merrill Lynch (South Africa): Merrill Lynch Africa (Pty) Ltd; Merrill Lynch (Milan): Merrill Lynch Il Lynch International Bank Ltd, Frankfurt Branch; Merrill Lynch (South Africa): Merrill Lynch (Asica): Merrill Lynch (Milan): Merrill Lynch (Irankfurt): Mer

This research report has been approved for publication in the United Kingdom by Merrill Lynch, Pierce, Fenner & Smith Limited and BASL, which are authorized and regulated by the Financial Services Authority; has been considered and distributed in Japan by Merrill Lynch Japan Securities Co, Ltd, a registered securities dealer under the Securities and Exchange Law in Japan; is distributed in Hong Kong by Merrill Lynch (Asia Pacific) Limited, which is regulated by the Hong Kong SFC and the Hong Kong Monetary Authority; is issued and distributed in Taiwan by Merrill Lynch Securities (Taiwan) Ltd.; is issued and distributed in Malaysia by Merrill Lynch (KL) Sdn. Bhd., a licensed investment adviser regulated by Malaysian Securities Commission; is issued and distributed in India by DSP Merrill Lynch Limited; and is issued and distributed in Singapore by Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd (Company Registration No.'s F 06872E and 198602883D respectively) and Bank of America Singapore Limited (Merchant Bank). Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd. are regulated by the Monetary Authority of Singapore. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 provides this report in Australia in accordance with section 911B of the Corporations Act 2001 and neither it nor any of its affiliates involved in preparing this research report is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this report in Brazil.

This research report has been prepared and issued by MLPF&S and/or one or more of its non-US affiliates. MLPF&S is the distributor of this research report in the US and accepts full responsibility for research reports of its non-US affiliates distributed to MLPF&S clients in the US. Any US person receiving this research report and wishing to effect any transaction in any security discussed in the report should do so through MLPF&S and not such foreign affiliates.

#### General Investment Related Disclosures:

This research report provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this report.

Securities and other financial instruments discussed in this report, or recommended, offered or sold by Merrill Lynch, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Merrill Lynch is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

UK Readers: The protections provided by the U.K. regulatory regime, including the Financial Services Scheme, do not apply in general to business coordinated by BofA Merrill Lynch entities located outside of the United Kingdom. BofA Merrill Lynch Global Research policies relating to conflicts of interest are described at http://www.ml.com/media/43347.pdf.

Officers of MLPF&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

MLPF&S or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. MLPF&S or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Merrill Lynch, through business units other than BofA Merrill Lynch Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented in this report. Such ideas or recommendations reflect the different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Merrill Lynch is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this report.

In the event that the recipient received this report pursuant to a contract between the recipient and MLPF&S for the provision of research services for a separate fee, and in connection therewith MLPF&S may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom MLPF&S has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by MLPF&S). MLPF&S is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities mentioned in this report.



Copyright and General Information regarding Research Reports:
Copyright 2010 Merrill Lynch, Pierce, Fenner & Smith Incorporated. All rights reserved. iQmethod, iQmethod 2.0, iQprofile, iQtoolkit, iQworks are service marks of Merrill Lynch & Co., Inc. iQanalytics®, iQcustom®, iQdatabase® are registered service marks of Merrill Lynch & Co., Inc. This research report is prepared for the use of BofA Merrill Lynch clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Merrill Lynch. BofA Merrill Lynch Global Research reports are distributed simultaneously to internal and client websites and other portals by BofA Merrill Lynch and are not publicly-available materials. Any unauthorized use or disclosure is prohibited. Receipt and review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment

recommendations, estimates or price targets) without first obtaining expressed permission from an authorized officer of BofA Merrill Lynch.

Materials prepared by BofA Merrill Lynch Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Merrill Lynch, including investment banking personnel. BofA Merrill Lynch has established information barriers between BofA Merrill Lynch Global Research and certain business groups. As a result, BofA Merrill Lynch does not disclose certain client relationships with, or compensation received from, such companies in research reports. To the extent this report discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this report. BofA Merrill Lynch Global Research personnel's knowledge of legal proceedings in which any BofA Merrill Lynch entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving companies mentioned in this report is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Merrill Lynch in connection with the legal proceedings or matters relevant to such proceedings.

This report has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of MLPF&S, any of its affiliates or their research analysts has any authority what soever to make any representation or warranty on behalf of the issuer(s). BofA Merrill Lynch Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Merrill Lynch and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This report may contain links to third-party websites. BofA Merrill Lynch is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by or any affiliation with BofA Merrill Lynch. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Merrill

Lynch is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Merrill Lynch policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment

Certain outstanding reports may contain discussions and/or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent research report relating to a company or issuer prior to making an investment decision.

In some cases, a company or issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any

investment opinion relating to such company or issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with MLPF&S or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Merrill Lynch nor any officer or employee of BofA Merrill Lynch accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents.